Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Related Keywords

Rachid Baz ,Department Of Malignant Hematology ,Pentecost Family Myeloma Research Center ,Moffitt Cancer Center ,Malignant Hematology ,D ,Patients With Multiple Myeloma ,Karmma 3 Trial ,